

29, 1999, the committee will discuss NDA 20-920, Natrecor® Injection (nesiritide), Scios, Inc., for short term treatment of congestive heart failure.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 18, 1999. Oral presentations from the public will be scheduled between approximately 9 a.m. and 10 a.m. on January 28, 1999. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 18, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 16, 1998

MA Friedman

Michael A. Friedman
Deputy Commissioner for Operations

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL

Jen Windsor

[FR Doc. 98-???? Filed ??-??-98; 8:45 am]

BILLING CODE 4160-01-F